Lindsay Pineau

post market success

How to Help Ensure Post-Market Success for Gene Therapies

Because of the increasing interest in the development of therapeutics for genetic conditions and rare diseases, we wanted to sit down with our VP of Life Sciences Business Development Sean Sigmon to get his perspective on what some forward-thinking organizations are doing to augment their go-to-market plans.  We want to help others understand some of the unique approaches that can be deployed when it comes to improving post-market access for genomic-based therapies. The following questions and answers highlight some concepts we believe biopharma marketers, commercial and market access teams should give strong consideration to.  

Clinical genomics guidance

Clinical Guidance: Rigorous, proactive, provider-friendly guidelines reduce abrasion and drive adoption

Appropriate clinical guidance is the cornerstone of any health plan benefits management program when it comes to genomics in healthcare.
However, writing and maintaining appropriate genomic coverage policies in-house poses unique challenges for most health plans. Genomic coverage guidelines must address many factors in the face of rapidly changing genomic science and a rapidly expanding test landscape.

What Patients, Providers, and Payors Should Know About Liquid Biopsies

By Heather Dorsey, Evidence Review Manager, M.S., CGC and Kelly Athman, Senior Director of Medical Affairs, M.S., CGC What is a liquid biopsy anyway? Your mind may be swirling with this and other questions, especially when it comes to more media coverage on these types of tests, like the recent article in The New York …

What Patients, Providers, and Payors Should Know About Liquid Biopsies Read More »

Strategies to Increase Diversity in Rare Genetic Disease Clinical Trials

By Rebecca Sutphen, MD, FACMGG, Co-Founder and Chief Medical Officer, InformedDNA, and Karmen Trzupek, MS, Board-Certified Genetic Counselor Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86% of genomics studies to date have involved people of European ancestry, which …

Strategies to Increase Diversity in Rare Genetic Disease Clinical Trials Read More »

Achieving Value through Comprehensive Genomic Benefits Management (GBM)

Executive Summary, by InformedDNA Precision medicine that harnesses advances in genomics holds enormous promise for impacting every aspect of a health plan’s business. When properly integrated, genomics enables more tailored care with the potential for tremendously improved outcomes–especially in specialties such as oncology and reproductive health. Genomics is a technically complex discipline with a growing …

Achieving Value through Comprehensive Genomic Benefits Management (GBM) Read More »

Solverwp- WordPress Theme and Plugin